Findings of Eurofins Discovery study indicate the potential of MYMD-1® to limit the fibrotic biology associated with idiopathic pulmonary fibrosis (IPF).
Findings of Eurofins Discovery study indicate the potential of MYMD-1® to limit the fibrotic biology associated with idiopathic pulmonary fibrosis (IPF).